NEFL and Alzheimer disease: Together, those successful results motivate further considerations of NfL as an outcome marker also in AD clinical trials, to evaluate how sensitive this biomarker is to identify downstream effects on neurodegeneration by drug candidates targeting amyloid and tau pathology.